Drug updated on 4/16/2024
| Dosage Form | Solution (topical: 10%) |
| Drug Class | Azole antifungals |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum and Trichophyton mentagrophytes.
Summary
- Efinaconazole (Jublia) is indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum and Trichophyton mentagrophytes, showing significant improvement over vehicle treatments in achieving complete and mycological cures.
- The information was derived from three studies that focused on or mentioned Jublia among other treatments for onychomycosis.
- Compared to ciclopirox 8% lacquer and tavaborole 5% solution, efinaconazole demonstrated superior outcomes in terms of achieving complete cures with high-quality evidence supporting its effectiveness; however, it has a slightly increased risk of adverse events such as dermatitis and vesicles.
- In comparison with oral treatments, which generally offer a greater likelihood of cure but come with higher risks requiring closer monitoring, efinaconazole presents an effective alternative, especially considering its favorable safety profile.
- Quality-of-life scores associated with onychomycosis improved across all treatment types, including efinaconazole; women and those with fingernail involvement reported poorer initial quality-of-life scores, indicating potential subgroup considerations.
- The choice between oral or topical treatments like efinaconazole should be individualized based on patient factors such as age, general health status, causative organism type, and number and extent of nail involvement, highlighting the importance of a personalized approach to therapy selection.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Jublia (efinaconazole) prescribing infromation. | 2022 | Bausch Health US LLC, Bridgewater, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Effect of onychomycosis and treatment on patient-reported quality-of-life outcomes: A systematic review. | 2021 | Journal of the American Academy of Dermatology |
| Topical and device-based treatments for fungal infections of the toenails (review). | 2020 | Cochrane Database of Systematic Reviews |
| Antifungal drug use for onychomycosis. | 2019 | American Journal of Therapeutics |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Therapeutic recommendations for the treatment of toenail onychomycosis in the US. | 2021 | Journal of Drugs in Dermatology |